First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

First‐in‐Human, Healthy Volunteers Integrated Protocol of ETC‐206, an Oral Mnk 1/2 Kinase Inhibitor Oncology Drug

In the last decade, drug development has tackled substantial challenges to improve efficiency and facilitate access to innovative medicines. Integrated clinical protocols and the investigation of targeted oncology drugs in healthy volunteers (HVs) have emerged as modalities with an increase in scope...

Full description

Bibliographic Details
Main Authors: Vincenzo Teneggi, Veronica Novotny‐Diermayr, Lay Hoon Lee, Maryam Yasin, Pauline Yeo, Kantharaj Ethirajulu, Sylvia Bong Hwa Gan, Stephanie E. Blanchard, Ranjani Nellore, Dhananjay N. Umrani, Roberto Gomeni, Darren Lim Wan Teck, Greg Li, Qing Shu Lu, Yang Cao, Alex Matter
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.12678

Internet

https://doi.org/10.1111/cts.12678

Similar Items